Angiogenesis in bladder tumours: Prognostic indicator and therapeutic target;L'angiogenèse dans les tumeurs vésicales : Indicateur pronostique et cible thérapeutique

Progres en Urologie

Volumn 11, Issue 3, 2001, Pages 417-427

  Chabannes, Eric ^a   Bernardini, Stéphane ^a   Wallerand, Hervé ^a   Bittard, Hugues ^a  

^a HÔPITAL SAINT JACQUES   (France)

Author keywords

Angiogenesis; Basic Fibroblast Growth Factor (bFGF); Bladder tumour; Prognosis; Vascular Endothelial Growth Factor (VEGF)

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

BLADDER TUMOR; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035380534     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. ALLEN L.E., MAHER P.A. : Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J. Cell. Physiol., 1993, 155 : 368-375.
2. ASAHARA T., BAUTERS C., ZHENG L.P., TAKESHITA S., BUNTING S., FERRARA N., SYMES J.F., ISNER J.M. : Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation, 1995, 92 : 365-371.
3. BABKOWSKI R.C. ZHANG H., XIA W.Y., ANTELO M., KATZ R.L., NG A., SHAKELFORD D., MARLEY G., VELTRI R., DINNEY C.P. : Angiogenesis does not have prognostic value in T1 bladder cancer. J. Urol., 1996, part 2, 155 : 615A, abstract 1215.
4. BEECKEN W.C., FERNANDEZ A., PANIGRAHY D., ACHILLES E., KISKER O., FLYNN E., JOUSSEN A.M., FOLKMAN J., SHING Y. : Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology, 2000, 56 : 521-526.
5. BERNARDINI S., HENRY P.C., FAUCONNET S., MARTIN M., CHABANNES E., ADESSI G.L., BITTARD H. : Intérêt de l'étude de l'expression du VEGF sérique dans les tumeurs urothéliales de la vessie. Prog. Urol., 2000, 10, O34, 9A.
6. BERSE B., BROWN L.F., VAN DE WATER L., DVORAK H.F., SENGER D.R. : Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol. Biol. Cell., 1992, 3 : 211-220.
7. BOCHNER B.H., COTE R.J., WEIDNER N., GROSHEN S., CHEN S.C., SKINNER D.G., NICHOLS P.W. : Angiogenesis in bladder cancer : relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst., 1995, 87 : 1603-1612.
8. BOUCK N., STELLMACH V., HSU S.C. : How tumors become angiogenic. Adv.Cancer Res., 1996, 69 : 135-174.
9. BROWN L.F., BERSE B., JACKMAN R.W., TOGNAZZI K., MANSEAU E.J., DVORAK H.F., SENGER D.R. : Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 1993,143 : 1255-1262.
10. CAMPBELL S.C. : Advances in angiogenesis research : relevance to urological oncology. J. Urol., 1997, 158 : 1663-1674.
11. CAMPBELL S.C., VOLPERT O.V., IVANOVICH M., BOUCK N.P.: Molecular mediators of angiogenesis in bladder cancer. Cancer Res., 1998, 58 : 1298-1304.
12. CHODAK G.W., HAUDENSCHILD C., GITTES R.F., FOLKMAN J. : Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann. Surg., 1980, 192 : 762-771.
13. CHODAK G.W., HOSPELHORN V., JUDGE S.M. , MAYFORTH R., KOEPPEN H., SASSE J. : Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res., 1988, 48 : 2083-2088.
14. CHODAK G.W., SCHEINER C.J., ZETTER B.R. : Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N. Engl. J. Med., 1981, 305 : 869-874.
15. CHODAK G.W., SUMMERHAYES I. : Detection of angiogenesis activity in malignant bladder tissue and cells. J. Urol., 1984, 132 : 1032-1035.
16. CHOPIN D.K., CARUELLE J.P., COLOMBEL M., PALCY S., RAVERY V., CARUELLE D., ABBOU C.C., BARRITAULT D. : Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol., 1993, 150 : 1126-1130.
17. CHOPIN D.K., POPOV Z., HOZNEK A., LEFRERE M.A., BELLOT J., ABBOU C.C. : p53 and angiogenesis in invasive bladder cancer. J. Urol., 1996, part 2, 155 : 690A, abstract 1518.
18. CHOW N.H., CHANG C.J., YEH T.M., CHAN S.H., TZAI T.S., LIN J.S. : Implications of urinary basic fibroblast growth factor excretion in patients with urothelial carcinoma. Clin. Sci., 1996, 90: 127-133.
19. CHOW N.H., LIU H.S., CHAN S.H., CHENG H.L., TZAI T.S. : Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res., 1999, 19 : 4593-4598.
20. CORDON-CARDO C., SHEINFELD J., DALBAGNI G. : Genetic-studies and molecular markers of bladder cancer. Semin. Surg. Oncol., 1997, 13 : 319-327.
21. CREW J.P. : Vascular endothelial growth factor : an important angiogenic mediator in bladder cancer. Eur. Urol., 1999, 35 : 2-8.
22. CREW J.P., FUGGLE S., BICKNELL R., CRANSTON D.W., DE BENEDETTI A., HARRIS A.L. : Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer, 2000, 82 : 161-166.
23. CREW J.P., O'BRIEN T., BICKNELL R., FUGGLE S., CRANSTON D., HARRIS A.L. : Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J. Urol., 1999, 161 : 799-804.
24. CREW J.P., O'BRIEN T., BRADBURN M., FUGGLE S., BICKNELL R., CRANSTON D., HARRIS A.L. : Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res., 1997, 57 : 5281-5285.
25. DICKINSON A.J., FOX S.B., PERSAD R.A., HOLLYER J., SIBLEY G.N.A., HARRIS A.L.: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol., 1994, 74 : 762-766.
26. DINNEY C.P., BIELENBERG D.R., PERROTTE P., REICH R., EVE B.Y., BUCANA C.D., FIDLER I.J. : Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res., 1998, 58 : 808-814.
27. DIRIX L.Y., VERMEULEN P.B., PAWINSKI A., PROVE A., BENOY I., DE POOTER C., MARTIN M., VAN OOSTEROM A.T. : Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Brit. J. Cancer. 1997, 76 : 238-243.
28. DVORAK H.F., BROWN L.F., DETMAR M., DVORAK A.M. : Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability and angiogenesis. Am. J. Pathol., 1995, 146 : 1029-1039.
29. EDER I.E., STENZL A., HOBISCH A., CRONAUER M.V., BARTSCH G., KLOCKER H. : Transforming growth factor-b1 and b2 in serum and urine from patients with bladder carcinoma. J. Urol., 1996, 156 : 953-957.
30. EDGREN M., LENNERNAS B., LARSSON A., NILSSON S : Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res., 1999, 19 : 869-874.
31. ELKIN M., ARIEL I., MIAO H.Q., NAGLER A., PINES M., DEGROOT N., HOCHBERG A., VLODAVSKY I. : Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res., 1999, 59 : 4111-4118.
32. FERRARA N. : Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 1999, 77 : 527-543.
33. FERRARA N., ALITALO K. : Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med., 1999, 5 : 1359-1364.
34. FERRARA N., DAVIS-SMYTH T. : The biology of vascular endothelial growth factor. Endocr. Rev., 1997,18 : 4-25.
35. FERRARA N., HENZEL W.J. : Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 1989, 161 : 851-858.
36. FOLKMAN J. : Angiogenesis in cancer, vascular rheumatoid and other disease. Nat. Med., 1995, 1 : 27-31.
37. FOLKMAN J. : Clinical applications of research on angiogenesis. N. Engl. J. Med., 1995, 333 : 1757-1763.
38. FOLKMAN J., MERLER E., ABERNATHY C., WILLIAMS G. : Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 1971, 133 : 275-288.
39. FOLKMAN J., SHING Y. : Angiogenesis. J. Biol. Chem., 1992, 267 : 10931-10934.
40. FUKUMURA D., XAVIER R., SUGIURA T., CHEN Y. PARK E.C., LU N., SELIG M., NIELSEN G., TAKSIR T., JAIN R.K., SEED B.: Tumor induction of VEGF promoter activity in stromal cells Cell, 1998, 94 : 715-725.
41. GANSLER T., VAGHMAR N., OLSON J.J., GRAHAM S.D. : Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J. Urol., 1992, 148 : 910-914.
42. GAZZANIGA P., GANDINI O., GRADILONE A., SILVESTRI I., GIULIANI L., MAGNANTI M., GALLUCCI M., SACCANI G., FRATI L., AGLIANO A.M. : Detection of basic fibioblast growth factor mRNA in urinary bladder cancer : correlation with local relapses. Int. J. Oncol., 1999, 14 : 1123-1127.
43. GINGRAS D., BELIVEAU R. : L'angiogenèse tumorale: une nouvelle cible thérapeutique anticancéreuse. Med. Sci., 1997, 13 : 1428-1435.
44. GROSSFELD G.D., GINSBERG D.A., STEIN J.P., BOCHNER B.H., ESRIG D., GROSHEN S., DUNN M., NICHOLS P.W., TAYLOR C.R., SKINNER D.G., COTE R.J. : Thrombospondin-1 expression in bladder cancer : association with p53 alterations, tumor angiogenesis and tumor progression. J. Natl. Cancer Inst., 1997, 89 : 219-227.
45. HANAHAN D., FOLKMAN J. : Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86 : 353-364.
46. HAWKE C.K., DELAHUNT B., DAVIDSON P.J. : Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder. Br. J. Urol., 1998, 81 : 585-590.
47. HOLMGREN L., O'REILLY M.S., FOLKMAN J. : Dormancy of micrometastases : balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1995, 1 : 149-153.
48. HORI A., SASADA R., MATSUTANI E., NAITO K., SAKURA Y., FUJITA T., KOZAI Y. : Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 1991, 51 : 6180-6184.
49. INOUE K., SLATON J.W., DAVIS D.W., HICKLIN D.J., McCONKEY D.J. KARASHIMA T., RADINSKY R., DINNEY C.P.N. : Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res., 2000, 6 : 2635-2643.
50. INOUE K., SLATON J.W., KARASHIMA T., YOSHIKAWA C., SHUIN T., SWEENEY P., MILLIKAN R., DINNEY C.P. : The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res., 2000, 6 : 4866-4873.
51. INOUE K., SLATON J.W., KIM S.J., PERROTTE P., EVE B.Y., BAR-ELI M., RADINSKY R., DINNEY C.P. : Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res., 2000, 60 : 2290-2299.
52. JACOBSEN J., RASMUSON T., GRANKVIST K., LJUNGBERG B. : Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol., 2000, 163 : 343-347.
53. JAEGER T.M., WEIDNER N., CHEW K., MOORE D.H . KERSCHMANN R.L., WALDMAN F.M., CARROLL P.R. : Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol., 1995, 154 : 69-71.
54. JONES A., CREW J. : Vascular endothelial growth factor and ist correlation with superficial bladder cancer recurrence rates and stage progression. Urol. Clin. North Am., 2000, 27 : 191-197.
55. JONES A., FUJIYAMA C. : Angiogenesis in urological malignancy : prognostic indicator and therapeutic target. BJU International, 1999, 83 : 535-556.
56. KIESER A., WEICH H.A., BRANDNER G., MARME D., KOLCH W. : Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 1994, 9 : 963-969.
57. KIM K.J., LI B., WINER J., ARMANINI M., GILLETT N., PHILLIPS H.S., FERRARA N. : Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 1993, 362 : 841-844.
58. KRAFT A., WEINDEL K., OCHS A., MARTH C., ZMIJA J., SCHUMACHER P., UNGER C., MARME D., GASTL G. : Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 1999, 85 : 178-187.
59. LAPHAM R.L., RO J.Y., STAERKEL G.A., AYALA A.G. : Pathology of transitional cell carcinoma of the bladder and its clinical implications. Semin. Surg. Oncol., 1997, 13 : 307-318.
60. LOPEZ J.I., ANGULO J.C. : The prognostic significance of vascular invasion in stage T1 bladder cancer. Histopathology, 1995, 27 : 27-33.
61. MIYAKE H., HARA I., YAMANAKA K., GOHJI K., ARAKAWA S., KAMIDONO S. : Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology. 1999, 53 : 302-307.
62. MIYAKE H., YOSHIMURA K., HARA I., ETO H., ARAKAWA S., KAMIDONO S. : Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J. Urol., 1997, 157 : 2351-2355
63. NEUFELD G., COHEN T., GENGRINOVITCH S., POLTORAK Z. : Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 1999, 13 : 9-22.
64. NGUYEN M., WATANABE H., BUDSON A.E., RICHIE J.P., FOLKMAN J. : Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst., 1993, 85 : 241-242.
65. NGUYEN M., WATANABE H., BUDSON A.E., RICHIE J.P., HAYES D.F., FOLKMAN J. : Elevated levels of an angiogenic peptide. basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst., 1994, 86 : 356-361.
66. NORRBY K. : Angiogenesis: new aspects relating to its initiation and control. A.P.M.I.S., 1997, 105 : 417-437.
67. O'BRIEN T., CRANSTON D., FUGGLE S., BICKNELL R., HARRIS A.L. : Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 1995, 55 : 510-513.
68. O'BRIEN T., CRANSTON D., FUGGLE S., BICKNELL R., HARRIS A.L. : Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res., 1997, 57 : 136-140.
69. O'BRIEN T.S., SMITH K., CRANSTON D., FUGGLE S., BICKNELL R., HARRIS A.L. : Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Brit. J. Urol., 1995, 76 : 311-314.
70. OEHLER M.K., BICKNELL R. : The promise of anti-angiogenic cancer therapy. Br. J. Cancer, 2000, 82 : 749-752.
71. O'REILLY M.S., HOLMGREN L., SHING Y., CHEN C., ROSENTHAL R.A., MOSES M., LANE W.S., CAO Y., SAGE E.H., FOLKMAN J. : Angiostatin : a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994, 79 : 315-328.
72. OSAWA S., TERASHIMA Y., KIMURA G., AKIMOTO M. : Antitumour effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. B.J.U. International, 1999, 83 : 123-128.
73. PEPPER M.S., FERRARA N., ORCI L., MONTESANO R. : Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun., 1992, 189 : 824-831.
74. PERROTTE P., MATSUMOTO T., INOUE K., KUNIYASU H., EVE B.Y., HICKLIN D.J., RADINSKY R., DINNEY C.P.N. : Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 1999, 5 : 257-264.
75. PESENTI E., SOLA F., MONGELLI N., GRANDI M., SPREAFICO F. : Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer, 1992, 66 : 367-372.
76. PHILP E.A., STEPHENSON T.J., REED M.W. : Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder. Br. J. Urol., 1996, 77 : 352-357.
77. POLTORAK Z., COHEN T., SIVAN R., KANDELIS Y., SPIRA G., VLODAVSKY I., KESHET E., NEUFELD G. : VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem., 1997, 272 : 7151-7158.
78. PRESTA L.G., CHEN H., O'CONNOR S.J., CHISHOLM V., MENG Y.G., KRUMMEN L., WINKLER M., FERRARA N. : Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57 : 4593-4599.
79. RAK J., MITSUHASHI Y., BAYKO L., FILMUS J., SHIRASAWA S., SASAZUKI T., KERBEL R.S. : Mutant ras oncogenes upregulate VEGF/VPF expression : implications for induction and inhibition of tumor angiogenesis. Cancer Res., 1995, 55 : 4575-4580.
80. RAVERY V., JOUANNEAU J., GIL DIEZ S., ABBOU C.C., CARUELLE J.P., BARRITAULT D., CHOPIN D.K. : Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol. Res., 1992, 20 : 211-214.
81. ROSEN E.M., JOSEPH A., JIN L., YAO Y., CHAU M.H.T., FUCHS A., GOMELLA L., HASTINGS H., GOLDBERG I.D., WEISS G.H. : Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J. Urol., 1997, 157 : 72-78.
82. SALVEN P., MANPAA H., ORPANA A., ALITALO K., JOENSUU H. : Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res., 1997, 3 : 647-651.
83. SATO K., SASAKI R., OGURA Y., SHIMODA N., TOGASHI H., TERADA K., SUGIYAMA T., KAKINUMA H., OGAWA O., KATO T. : Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J. Exp. Med., 1998, 185 : 173-184.
84. SENGER D.R., GALLI S.J., DVORAK A.M., PERRUZZI C.A., HARVEY V.S., DVORAK H.F. : Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219 : 983-985..
85. SHING Y., FOLKMAN J., SULLIVAN R., BUTTERFIELD C., MURRAY J., KLAGSBRUN M. : Heparin affinity : purification of a tumor-derived capillary endothelial cell growth factor. Science, 1984, 223 : 1296-1299.
86. SINGH R.K., GUTMAN M., BUCANA C.D., SANCHEZ R., LLANSA N., FIDLER I.J. : Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci., 1995, 92 : 4562-4566
87. SLATON J.W., PERROTTE P., INOUE K., DINNEY C.P., FIDLER I.J. : Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 1999, 5: 2726-2734.
88. STEIN J.P., GROSSFELD G.D., GINSBERG D.A., ESRIG D., FREEMAN J.A., FIGUEROA A.J., SKINNER D.G., COTE R.J. : Prognostic markers in bladder cancer: a comtemporary review of the literature. J. Urol., 1998, 160 : 645-659.
89. TANAKA Y., KAWAMATA H., FUJIMOTO K., OYASU R. : Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J. Urol., 1997, 157 : 683-688.
90. TISCHER E., MITCHELL R., HARTMAN T., SILVA M., GOSPODAROWICZ D., FIDDES J.C., ABRAHAM J.A. : The human gene for vascular endothelial growth factor. J. Biol. Chem., 1991, 266 : 11947-11954.
91. WAKUI S., FURUSATO M., SASAKI S., MUTO T., TAKAHASHI H., MASAOKA T., USHIGOME S. : Expression of vascular endothelial growth factor in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis. Vet. Pathol., 1999, 36 : 111-116.
92. WALTHER M.M., FIGG W.D., LINEHAN W.M. : Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J. Urol., 1996, 14 : S8-S11.
93. YOSHIMURA K., ETO H., MIYAKE H., HARA I., ARAKAWA S., KAMIDONO S. : Messenger ribonucleic acids for fibroblast growth factors and their receptor in bladder and renal cell carcinoma cell lines. Cancer Lett., 1996, 103 : 91-97.
94. ZHANG H.T., CRAFT P., SCOTT P.A., ZICHE M., WEICH H.A., HARRIS A.L., BICKNELL R. : Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J. Natl. Cancer Inst., 1995, 87 : 213-219.
95. ZHOU J.R., MUKHERJEE P., GUGGER E.T., TANAKA T., BLACKBURN G.L., CLINTON S.K. : Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in cell cycle, apoptosis, and angiogenesis. Cancer Res., 1998, 58 : 5231-5238.